Trump’s Deal on Obesity Drugs: Real Relief or Political Show?
President Trump’s announcement on lowering obesity drug costs sounds promising—but does it deliver real savings for American families or merely serve as political theater ahead of elections?
Is This New Deal a Win for American Patients or Just Pharma-Friendly Posturing?President Donald Trump recently announced a high-profile deal with Eli Lilly and Novo Nordisk to expand coverage and cut prices on popular obesity drugs Zepbound and Wegovy. At first glance, this appears to be a bold step forward—finally addressing the crushing cost barrier that keeps life-changing medications out of reach for millions of Americans struggling with obesity.Yet, beneath the surface, the fine print raises serious questions. These GLP-1 receptor agonists command monthly prices around $500 at higher doses, an expense many working Americans simply cannot afford—even with insurance....
This is Exclusive Content for Subscribers
Join our community of patriots to read the full story and get access to all our exclusive analysis.
View Subscription Plans